Charles River Laboratories International, Inc.
CRL · NYSE
12/31/2024 | 12/28/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $9,484,748 | – | $12,110,063 | $11,071,935 |
| - Cash | $194,606 | $194,606 | $276,771 | $233,912 |
| + Debt | $2,723,994 | $2,723,994 | $3,066,381 | $3,097,276 |
| Enterprise Value | $12,014,136 | – | $14,899,673 | $13,935,299 |
| Revenue | – | $4,049,989 | $4,129,409 | $3,976,060 |
| % Growth | – | -1.9% | 3.9% | – |
| Gross Profit | – | $1,331,821 | $1,502,556 | $1,462,651 |
| % Margin | – | 32.9% | 36.4% | 36.8% |
| EBITDA | – | $581,143 | $1,032,118 | $986,148 |
| % Margin | – | 14.3% | 25% | 24.8% |
| Net Income | – | $10,297 | $474,624 | $486,226 |
| % Margin | – | 0.3% | 11.5% | 12.2% |
| EPS Diluted | – | 0.2 | 9.22 | 9.48 |
| % Growth | – | -97.8% | -2.7% | – |
| Operating Cash Flow | – | $734,577 | $683,898 | $619,640 |
| Capital Expenditures | – | -$232,967 | -$318,528 | -$324,733 |
| Free Cash Flow | – | $501,610 | $365,370 | $294,907 |